Oct 29, 2018 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Oct 26, 2018 - We take a look at a few stocks that might deliver an earnings beat when they report next week.
Oct 26, 2018 - Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Oct 26, 2018 - Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.
Oct 24, 2018 - United Health's (UHS) third quarter is likely to gain from solid segmental performances and higher number of admissions.
Oct 24, 2018 - While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Oct 18, 2018 - Centene's (CNC) third quarter should exhibit strong performances by its Government-backed and Medicaid businesses.
Oct 17, 2018 - EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
Oct 17, 2018 - Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
Oct 03, 2018 - Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.